國家衛生研究院 NHRI:Item 3990099045/13558
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 908268      Online Users : 972
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13558


    Title: A novel recombinant Fc gamma receptor-targeted survivin combines with chemotherapy for efficient cancer treatment
    Other Titles: A novel recombinant Fcγ receptor-targeted survivin combines with chemotherapy for efficient cancer treatment
    Authors: Wu, CC;Chiang, CY;Liu, SJ;Chen, HW
    Contributors: National Institute of Infectious Diseases and Vaccinology
    Abstract: Formyl peptide receptor-like 1 inhibitor (FLIPr), an Fc gamma receptor (Fc gamma R) antagonist, can be used as a carrier to guide antigen-FLIPr fusion protein to Fc gamma R then enhances antigen-specific immune responses. Survivin, a tumor-associated antigen, is over-expressed in various types of human cancer. In this study, we demonstrate that recombinant survivin-FLIPr fusion protein (rSur-FLIPr) binds to Fc gamma Rs, and efficient uptake by dendritic cells in vivo. In addition, rSur-FLIPr alone stimulates survivin-specific immune responses, which effectively suppresses the tumor growth. The antitumor immunities are through TAP-mediated and CD8-dependent pathways. Furthermore, preexisting anti-FLIPr antibody does not abolish antitumor responses induced by rSur-FLIPr immunization. These results suggest that FLIPr is an effective antigen delivery vector and can be repeatedly used. Combination of chemotherapy with rSur-FLIPr treatment reveals a great benefit to tumor-bearing mice. Altogether, these findings suggest that rSur-FLIPr is a potential candidate for efficient cancer therapy.
    Date: 2021-07-12
    Relation: Biomedicines. 2021 Jul 12;9(7):Article number 806.
    Link to: http://dx.doi.org/10.3390/biomedicines9070806
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2227-9059&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000676540900001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85111008738
    Appears in Collections:[Hsin-Wei Chen] Periodical Articles
    [Shih-Jen Liu] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000676540900001.pdf8768KbAdobe PDF232View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback